Breaking News Instant updates and real-time market news.

TEVA

Teva

$32.34

-0.11 (-0.34%)

08:05
07/31/17
07/31
08:05
07/31/17
08:05

Celltrion, Teva announce FDA acceptance of BLA for Herceptin biosimilar

Celltrion and Teva Pharmaceutical announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for CT-P6, a proposed Monoclonal Antibody biosimilar to Herceptin, which is used for the treatment of Human Epidermal growth factor Receptor 2-overexpressing breast cancer and metastatic gastric cancer. The BLA for CT-P6 includes data for CT-P6 and reference trastuzumab in terms of efficacy, safety, immunogenicity, pharmacodynamics and pharmacokinetics. These trials were conducted in over 500 patients in 22 countries. CT-P6 has been approved by the Korean Ministry of Food and Drug Safety. Celltrion also filed marketing authorization applications for CT-P6 to the European Medicines Agency in October 2016. Celltrion and Teva entered into an exclusive partnership to commercialize CT-P6 and CT-P10 in the U.S. and Canada in October 2016.

  • 03

    Aug

  • 30

    Aug

TEVA Teva
$32.34

-0.11 (-0.34%)

07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
07/18/17
WELS
07/18/17
NO CHANGE
WELS
Market Perform
Novartis report has cautious read-through for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:49
08/18/17
08/18
16:49
08/18/17
16:49
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$30.38

0.76 (2.57%)

16:48
08/18/17
08/18
16:48
08/18/17
16:48
Hot Stocks
Micron director sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

INSY

Insys Therapeutics

$9.17

-0.11 (-1.19%)

16:42
08/18/17
08/18
16:42
08/18/17
16:42
Hot Stocks
Insys agrees to pay $4.45M to settle opioid marketing suit »

Illinois Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.11

-0.04 (-0.44%)

16:32
08/18/17
08/18
16:32
08/18/17
16:32
Hot Stocks
Jamba receives expected letter from Nasdaq »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$4.50

0.2 (4.65%)

16:31
08/18/17
08/18
16:31
08/18/17
16:31
Hot Stocks
Hill International receives NYSE notice regarding late Form 10-Q filing »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$55.65

-0.47 (-0.84%)

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Periodicals
Target ends relationship with food startup Hampton Creek, Bloomberg says »

After an internal review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Options
Preliminary option volume of 23.2M today »

Preliminary option volume…

NBEV

New Age Beverages

$3.51

-0.49 (-12.25%)

16:29
08/18/17
08/18
16:29
08/18/17
16:29
Hot Stocks
New Age Beverages director sells nearly 42,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

, ESV

Ensco

$4.28

0.12 (2.88%)

16:24
08/18/17
08/18
16:24
08/18/17
16:24
Hot Stocks
Atwood Oceanics, Ensco file proxy materials in connection with pending merger »

Ensco (ESV) and Atwood…

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

ESV

Ensco

$4.28

0.12 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$83.76

-0.1 (-0.12%)

16:23
08/18/17
08/18
16:23
08/18/17
16:23
Periodicals
Nestle faces potential fraud suit over Poland Spring marketing, WSJ says »

Nestle is facing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.